Skip to content
Henrik Ahlenius

Image -

Henrik Ahlenius

Henrik Ahlenius, Lunds University, has the BRIDGE Sweden project “In Vivo Gene Therapy for Glioblastoma” together with Johan Bengzon.
Tove Smeds/Lunds universitet
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
By:
Tove Smeds/Lunds universitet
File format:
.jpg
Size:
5430 x 3624, 3.69 MB
Download

Topics

Contacts

Related content

  • The leaders of the four selected pilot projects in BRIDGE Sweden: Anna Dimberg, Uppsala university, Thuy Tran, KI, Maarten de Château, Buzzard Pharmaceuticals, and Henrik Ahlenius and Johan Bengzon, Lunds university.

    Four pilot projects to lead the way in BRIDGE Sweden

    Four pilot projects will receive dedicated support to accelerate the commercialization of their specific biological product through BRIDGE Sweden. The projects, three Academic and one start-up, will set the standard, help to identify essential offerings and refine the approach at SciLife Lab’s DDD platform, Testa Center and Lund’s Stem Cell Center and pre-GMP facility.